Altre lingue Torii Pharmaceutical Co., Ltd.

Azioni

4551

JP3635800000

Mercato chiuso - Japan Exchange Altri mercati azionari 08:00:00 26/04/2024			Variaz. 5gg	Var. 1 gen.
3.855 ^JPY	+1,72%		+4,47%	+8,44%

13/02	LIM Advisors ritira parzialmente la proposta degli azionisti	CI
09/02	Torii Pharmaceuticals si oppone alla proposta degli azionisti	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

LIM Advisors Partially Withdraws Shareholder Proposal	13/02
Torii Pharmaceuticals Opposes Shareholder Proposal	09/02
Torii Pharmaceutical - Top-line Results of Phase 3 Clinical Study of TO-208 for the Treatment of Molluscum Contagiosum in Japan	18/12
Verrica Pharmaceuticals Development and Commercialization Partner, Torii Pharmaceutical Co., Ltd., Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208	18/12
Verrica Pharmaceuticals' Partner Reports Positive Data From Phase 3 Trial of Skin Infection Treatment	15/12
Torii Pharmaceutical : Top-line Results of Phase 3 Clinical Study of TO-208 for the Treatment of Molluscum Contagiosum in Japan	15/12
Torii Pharmaceutical Co., Ltd. Announces Positive Top-Line Results from a Confirmatory Phase 3 Trial of TO-208 for the Treatment of Molluscum Contagiosum in Japan	15/12
Torii Pharmaceutical : Signing of an Agreement for the Exclusive Development and Commercialization of GRAZAX®,an Allergen Immunotherapy (Sublingual Immunotherapy) Drug for Grass Pollinosis in Japan	13/12
ALK Abello Adds Grass Pollen Allergy Drug to Torii License Deal in Japan	12/12
ALK-Abelló A/S Expands Partnership with Torii Pharmaceutical Co., Ltd. in Japan	12/12
BioCryst Amends Deal With Torii Pharmaceutical for Orladeyo's Commercialization in Japan; Shares Rise	30/11
Torii Pharmaceutical : Financial Results for the First Nine Months of Fiscal Year Ending December 2023	31/10/23
Torii Pharmaceutical - JT Files New Drug Application of JTE-061 Cream, Aryl hydrocarbon Receptor agonist, for the Treatment of Atopic Dermatitis and Plaque Psoriasis in Japan	18/09/23
Torii Pharmaceutical : JT Files New Drug Application of JTE-061 Cream,Aryl hydrocarbon Receptor (AhR) agonist,for the Treatment of Atopic Dermatitis and Plaque Psoriasis in Japan	15/09/23
Torii Pharmaceutical : Financial Results for the First Three Months of Fiscal Year Ending December 2023	28/04/23
Torii Pharmaceutical Announces Voting Results	30/03/23
Torii Pharmaceutical : Views on Report from ISS, a Proxy Advisory Firm, On Proposals for ’s General Meeting of Shareholders	16/03/23
Torii Pharmaceutical : Notice of the Opinion of the Board of Directors Regarding the Shareholder Proposal	17/02/23
Torii has announced Medium-Term Management Plan 2023-2025	13/02/23
Torii Pharmaceutical : has announced Medium-Term Management Plan 2023-2025	10/02/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Torii Pharmaceutical Co., Ltd.

Azioni

4551

JP3635800000

Altre lingue

Filtri